CAS 475207-59-1
:Nexavar
Descrição:
Nexavar, com o número CAS 475207-59-1, é o nome comercial do sorafenibe, um inibidor de tirosina quinase de pequenas moléculas usado principalmente no tratamento do câncer. É caracterizado por sua capacidade de inibir múltiplas quinases envolvidas na proliferação de células tumorais e angiogênese, incluindo quinases Raf e quinases de receptor de tirosina como VEGFR e PDGFR. O sorafenibe é tipicamente administrado por via oral e é conhecido por seu papel no tratamento do carcinoma de células renais avançado e do carcinoma hepatocelular. O composto é um sólido amarelo pálido a branco sujo, com uma fórmula molecular que inclui carbono, hidrogênio, nitrogênio, oxigênio e flúor. Seu mecanismo de ação envolve a interrupção das vias de sinalização que promovem o crescimento de células cancerosas e a formação de vasos sanguíneos, retardando assim a progressão do tumor. Nexavar é frequentemente associado a efeitos colaterais como fadiga, diarreia e reações cutâneas, que são considerações importantes na gestão do paciente. No geral, o sorafenibe representa um avanço significativo nas terapias direcionadas ao câncer, oferecendo uma abordagem estratégica para combater malignidades específicas.
Fórmula:C21H16ClF3N4O3·C7H8SO3
InChI:InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
Chave InChI:InChIKey=IVDHYUQIDRJSTI-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2.S(=O)(=O)(O)C1=CC=C(C)C=C1
Sinónimos:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1)
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate)
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
- BAY 43-9006 mono-p-tosylate
- Bay 54-9085
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate
- Nexavar
- Sorafenib TsOH salt
- Sorafenib p-toluenesulfonate
- Sorafenib-D3
- Sorafenib tosylate
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
19 produtos.
Sorafenib Tosylate
CAS:Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:>98.0%(T)(HPLC)Cor e Forma:White to Light yellow powder to crystalPeso molecular:637.03Sorafenib Tosylate
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFórmula:C21H16ClF3N4O3·C7H8O3SCor e Forma:White Brown PowderPeso molecular:636.105724-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic acid
CAS:Fórmula:C28H24ClF3N4O6SPureza:98%Cor e Forma:SolidPeso molecular:637.0266Sorafenib tosylate
CAS:<p>Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).</p>Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:99.24% - 99.94%Cor e Forma:White To Off-White Crystalline PowderPeso molecular:637.03Sorafenib tosylate
CAS:Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:≥ 98.0% (dried basis)Cor e Forma:White, off-white or pale yellow-brown powderPeso molecular:637.03Sorafenib Tosylate
CAS:Fórmula:C21H16ClF3N4O3·C7H8O3SCor e Forma:Off-White SolidPeso molecular:464.83 172.20Sorafenib Tosylate
CAS:Produto ControladoFórmula:C21H16ClF3N4O3·C7H8O3SCor e Forma:NeatPeso molecular:637.03Sorafenib tosylate
CAS:<p>Sorafenib tosylate</p>Fórmula:C21H16ClF3N4O3·C7H8O3SPureza:99%Cor e Forma: off-white solidPeso molecular:637.03g/molSorafenib Tosylate
CAS:Produto ControladoFórmula:C21H16ClF3N4O3·C7H8O3SCor e Forma:NeatPeso molecular:637.03Sorafenib tosylate
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Fórmula:C21H16ClF3N4O3•C7H8O3SPureza:Min. 95%Cor e Forma:Off-White PowderPeso molecular:637.03 g/molSorafenib tosylate - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib tosylate also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib tosylate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Fórmula:C21H16ClF3N4O3•C7H8O3SPureza:Min. 95%Cor e Forma:PowderPeso molecular:637.03 g/molSorafenib, p-Toluenesulfonate Salt
CAS:Fórmula:C35H30F3N7O4SPureza:98%Cor e Forma:SolidPeso molecular:701.73
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0035M4.jpg&w=3840&q=75)
